Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

AMMONUL

SODIUM BENZOATE; SODIUM PHENYLACETATE

Standard Dose
10%;10% (5GM/50ML;5GM/50ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview AMMONUL is listed in Drugs@FDA under application 020645 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient SODIUM BENZOATE; SODIUM PHENYLACETATE Form and strength SOLUTION;INTRAVENOUS - 10%;10% (5GM/50ML;5GM/50ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAUSCH Submission history Latest submission status date: 2020-12-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview AMMONUL is listed in Drugs@FDA under application 020645 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient SODIUM BENZOATE; SODIUM PHENYLACETATE Form and strength SOLUTION;INTRAVENOUS - 10%;10% (5GM/50ML;5GM/50ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAUSCH Submission history Latest submission status date: 2020-12-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.